HRP20080272T3 - Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor - Google Patents

Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor

Info

Publication number
HRP20080272T3
HRP20080272T3 HR20080272T HRP20080272T HRP20080272T3 HR P20080272 T3 HRP20080272 T3 HR P20080272T3 HR 20080272 T HR20080272 T HR 20080272T HR P20080272 T HRP20080272 T HR P20080272T HR P20080272 T3 HRP20080272 T3 HR P20080272T3
Authority
HR
Croatia
Prior art keywords
polysubstituted
unsubstituted
mono
alkyl
cycloalkyl
Prior art date
Application number
HR20080272T
Other languages
English (en)
Croatian (hr)
Inventor
Hinze Claudia
Sundermann Bernd
Schick Hans
Henkel Birgitta
Englberger Werner
Oberb�rsch Stefan
Friderichs Elmar
Frormann Sven
K�gel Babette-Yvonne
Linz Klaus
Merla Beatrix
Saunders Derek
Schr�der Wolfgang
Original Assignee
Grnenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grnenthal Gmbh filed Critical Grnenthal Gmbh
Publication of HRP20080272T3 publication Critical patent/HRP20080272T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20080272T 2003-12-23 2008-06-18 Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor HRP20080272T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10360792A DE10360792A1 (de) 2003-12-23 2003-12-23 Spirocyclische Cyclohexan-Derivate
PCT/EP2004/014539 WO2005066183A1 (de) 2003-12-23 2004-12-21 Spirocyclische cyclohexan-derivate mit affinität zum orl1-rezeptor

Publications (1)

Publication Number Publication Date
HRP20080272T3 true HRP20080272T3 (en) 2008-09-30

Family

ID=34706497

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080272T HRP20080272T3 (en) 2003-12-23 2008-06-18 Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor

Country Status (28)

Country Link
US (1) US7332519B2 (xx)
EP (1) EP1725567B1 (xx)
JP (1) JP4885733B2 (xx)
KR (1) KR101152693B1 (xx)
CN (1) CN1922189B (xx)
AR (1) AR047163A1 (xx)
AT (1) ATE390430T1 (xx)
AU (1) AU2004312147B2 (xx)
BR (1) BRPI0418052A2 (xx)
CA (1) CA2550868C (xx)
CY (1) CY1107975T1 (xx)
DE (2) DE10360792A1 (xx)
DK (1) DK1725567T3 (xx)
EC (1) ECSP066667A (xx)
ES (1) ES2303964T3 (xx)
HK (1) HK1095831A1 (xx)
HR (1) HRP20080272T3 (xx)
IL (1) IL176457A (xx)
MX (1) MXPA06007171A (xx)
NO (1) NO337127B1 (xx)
NZ (1) NZ548317A (xx)
PE (1) PE20050758A1 (xx)
PL (1) PL1725567T3 (xx)
PT (1) PT1725567E (xx)
RU (1) RU2383544C2 (xx)
SI (1) SI1725567T1 (xx)
WO (1) WO2005066183A1 (xx)
ZA (1) ZA200606067B (xx)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033114A1 (de) * 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
EP1894938A1 (en) * 2006-08-31 2008-03-05 Evonik Degussa GmbH New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102007009235A1 (de) * 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
AU2009204048B2 (en) * 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
WO2009118174A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH Substituierte cyclohexyldiamine
MX2010010337A (es) * 2008-03-27 2010-10-07 Gruenenthal Gmbh Derivados de espiro(5.5)undecano.
ES2663398T3 (es) 2008-03-27 2018-04-12 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
AR071066A1 (es) 2008-03-27 2010-05-26 Gruenenthal Chemie Derivados de (hetero) aril-ciclohexano
CL2009000732A1 (es) * 2008-03-27 2009-05-15 Gruenethal Gmbh Compuestos derivados de hidroximetil ciclohexilaminas sustituidos; composicion farmaceutica que contiene a dicho compuesto y sus uso como moduladores del receptor de opiodes u y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso del alcohol, hipertension, anorexia, obesidad y diarrea.
DK2260042T3 (da) * 2008-03-27 2011-10-31 Gruenenthal Gmbh Substituerede spirocykliske cyklohexan-derivater
SI2273983T1 (sl) 2008-05-09 2016-11-30 Gruenenthal Gmbh Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
CA2741018A1 (en) 2008-11-13 2010-05-20 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
DK2501704T3 (da) * 2009-11-16 2013-10-14 Lilly Co Eli Spiropiperidinforbindelser som oral-1-receptorantagonister
PT2585469T (pt) 2010-06-24 2016-08-29 Leo Pharma As Compostos heterocíclicos de benzodioxolo ou benzodioxepina como inibidores da fosfodiesterase
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
WO2012028317A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130202701A1 (en) * 2012-02-03 2013-08-08 Gruenenthal Gmbh (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
NO2846835T3 (xx) 2012-05-11 2018-02-03
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320729B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310385A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
PL2970284T3 (pl) 2013-03-15 2018-03-30 Grünenthal GmbH Krystaliczna cis-(E)-4-(3-fluorofenylo)-2',3',4',9'-tetrahydro-N,N-dimetylo-2'-(1-okso-3-fenylo-2-propenylo)-spiro[cykloheksano-1,1'[1H]-pirydo[3,4-b]indolo]-4-amina
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3082781A1 (en) 2013-12-16 2016-10-26 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CA2955071A1 (en) 2014-07-15 2016-01-21 Grunenthal Gmbh Substituted azaspiro(4.5)decane derivatives
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
EP3253376A1 (en) 2015-02-03 2017-12-13 Grünenthal GmbH Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3481378A1 (en) 2016-07-06 2019-05-15 Grünenthal GmbH Reinforced pharmaceutical dosage form

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ATE229954T1 (de) * 1998-06-12 2003-01-15 Sod Conseils Rech Applic Betacarbolinverbindungen
CA2356269A1 (en) * 1998-12-24 2000-07-06 Yoshihisa Akiyama Pain control agent
DE10044649A1 (de) * 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate

Also Published As

Publication number Publication date
CN1922189B (zh) 2010-06-16
CY1107975T1 (el) 2013-09-04
CA2550868C (en) 2012-03-06
NO337127B1 (no) 2016-01-25
WO2005066183A1 (de) 2005-07-21
CA2550868A1 (en) 2005-07-21
EP1725567B1 (de) 2008-03-26
DK1725567T3 (da) 2008-06-16
KR20070014117A (ko) 2007-01-31
PT1725567E (pt) 2008-05-09
PL1725567T3 (pl) 2008-09-30
BRPI0418052A2 (pt) 2017-04-18
EP1725567A1 (de) 2006-11-29
ECSP066667A (es) 2006-10-25
US20050192333A1 (en) 2005-09-01
NZ548317A (en) 2010-01-29
ATE390430T1 (de) 2008-04-15
MXPA06007171A (es) 2006-08-23
AU2004312147A1 (en) 2005-07-21
RU2006126787A (ru) 2008-01-27
ZA200606067B (en) 2007-10-31
IL176457A0 (en) 2006-10-05
JP2007515446A (ja) 2007-06-14
JP4885733B2 (ja) 2012-02-29
AU2004312147B2 (en) 2010-06-10
DE502004006697D1 (de) 2008-05-08
SI1725567T1 (sl) 2008-06-30
RU2383544C2 (ru) 2010-03-10
HK1095831A1 (en) 2007-05-18
DE10360792A1 (de) 2005-07-28
KR101152693B1 (ko) 2012-06-15
ES2303964T3 (es) 2008-09-01
US7332519B2 (en) 2008-02-19
IL176457A (en) 2013-11-28
NO20063422L (no) 2006-09-25
CN1922189A (zh) 2007-02-28
AR047163A1 (es) 2006-01-11
PE20050758A1 (es) 2005-10-18

Similar Documents

Publication Publication Date Title
HRP20080272T3 (en) Spirocyclic cyclohexane derivatives with affinity to the orl-1 receptor
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
HRP20080531T3 (en) Hiv integrase inhibitors: cyclic pyrimidinone compounds
BRPI0806796A2 (pt) derivados de ciclohexano espiro cìclico
RS53347B (en) TOLL-SIMILAR RECEPTOR MODULATORS
CO5690642A2 (es) Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibi- dores de fosfodiesterasa
ES2618003T3 (es) Compuestos tricíclicos sustituidos como inhibidores de FGFR
CA2633444A1 (en) Organo-modified silica based material
Sancibrao et al. Synthetic Approaches to Racemic Porantheridine and 8-Epihalosaline via a Nitroso Diels− Alder Cycloaddition/Ring-Rearrangement Metathesis Sequence
Mutoh et al. Photochromism of a water-soluble vesicular [2.2] paracyclophane-bridged imidazole dimer
De Kimpe et al. Synthesis of α-cyanoenamines: Isolation and characterization of both tautomeric isomers: α-cyanoenamines and imidoylcyanides
Yuan et al. A convenient and effective synthesis of tris-bridged tricationic azolophanes
CN208091877U (zh) 一种透水混凝土渗透测试装置
LT6105B (lt) Spiro[chroman-2,2'-indolo] dariniai kaip cianido jonų chemosensoriai
IL185015A (en) Process for the manufacture of a camptothecin intermediate
CN103513268B (zh) 一种地震物理储层模型及其制备方法和应用
Gong et al. Acidichromism in the Langmuir–Blodgett films of novel photochromic spiropyran and spirooxazine derivatives
CN106432217A (zh) 一种含咔唑基及噁二唑基Schiff碱及其制备方法
AR049450A1 (es) Derivados de tetrahidrofurano tetraciclicos insaturados
ITMI982842A1 (it) Composti fotocromatici, procedimento per la loro preparazione e loroutilizzo in materiali polimerici.
Graus et al. Supramolecular arrangements based on cyclohexane-5-spirohydantoin derivatives
Kurata et al. Novel monocation, dication, and dianion of a cage molecule, trithienylmethanophane
Grigor’ev Peculiarities of chemical properties of imidazole-derived and other types of cyclic nitrones and their use in Organic Synthesis
RU2011111101A (ru) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 5,8,9,10-ТЕТРАГИДРОПИРИМИДО [4,5-d]АЗОЦИНОВ, ИМЕЮЩИХ В 4-М ПОЛОЖЕНИИ ТРИФЛАТНУЮ, ВТОРИЧНУЮ И ТРЕТИЧНУЮ АМИНОГРУППЫ
EP1767530A4 (en) BENZOXAZOLES